Glucose‐lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification
Carol Pollock, Juan Jose Garcia Sanchez, Juan‐Jesus Carrero, Supriya Kumar, Roberto Pecoits‐Filho, Carolyn S. P. Lam, Hungta Chen, Eiichiro Kanda, Mitja Lainscak, David C. Wheeler- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Abstract
Aims
To describe treatment pathways for key glucose‐lowering therapies in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D) using retrospective data from DISCOVER CKD (NCT04034992).
Methods
Data were extracted from the UK Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics data (2008–2020) and the US integrated Limited Claims and Electronic Health Records Database (LCED; 2012–2019). Eligible individuals were aged ≥18 years with CKD, identified by two consecutive estimated glomerular filtration rate (eGFR) measures (15–<75 mL/min/1.73 m2; 90–730 days apart; index date was the second measurement) and T2D. Chronological treatment pathways for glucose‐lowering therapies prescribed on or after CKD index to end of follow‐up were computed. Median time and proportion of overall follow‐up time on treatment were described for each therapy by database and by eGFR and urinary albumin‐to‐creatinine ratio (UACR) categories.
Results
Of 36,951 and 4339 eligible individuals in the CPRD and LCED, respectively, median baseline eGFR was 67.8 and 64.9 mL/min/1.73 m2; 64.2 and 63.9% received metformin prior to index; and median (interquartile range) time on metformin during follow‐up was 917 (390–1671) and 454 (192–850) days (accounting for ~75% of follow‐up time in both databases). The frequency of combination treatment increased over time. There were trends towards decreased metformin prescriptions with decreasing eGFR and increasing UACR within each eGFR category.
Conclusions
Individuals with CKD and T2D had many combinations of therapies and substantial follow‐up time on therapy. These results highlight opportunities for improved CKD management.